-
ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation to its bispecific antibody (BsAb)-receptor recombinant protein IMM2902, targeting human CD47 and HER2. The product is the only CD47/HER2 BsAb to enter clinical trials globally. Drug ProfileIMM2902 inhibits tumor cell growth by…
-
VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed
•
China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products worth over RMB4.4 billion ($651 million). The results, released by VBP authorities, show Shijiazhuang No. 4 Pharmaceutical Co. Ltd as the top contract winner, while six foreign firms secured deals totaling RMB76.7 million (1.7% of…
-
Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000
•
Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up to €100,000 ($101,000) to startups in healthcare, life science, electronics, and smart manufacturing. The initiative aims to identify early-stage companies and support proof-of-concept studies, pilot projects, and partnerships with Merck. Program DetailsUptune is open to…
-
Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach
•
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell lung cancer (NSCLC), marking the PD-L1 inhibitor’s second approved indication in the country. The therapy, developed by CStone Pharmaceuticals (HKG: 2616) under a license from Ligand Pharmaceuticals (NASDAQ: LGND), is now the only immunotherapy approved…
-
Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of its generic drug and “non-core” conventional medicine businesses. The move follows a strategic review aimed at refocusing resources on higher-growth sectors. Strategic RationaleThe board intends to offload products not aligned with performance expectations or long-term…
-
Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment
•
China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for lurbinectedin (LY01017), an RNA polymerase II inhibitor, to treat metastatic small-cell lung cancer (SCLC) in patients with disease progression after chemotherapy. The drug will be available through Hainan’s Boao Lecheng International Medical Tourism Pilot Zone,…
-
Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline
•
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including…
-
Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection
•
Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of money in an angel financing round. The sole contributor to the round was ASB Ventures. The proceeds will be used to promote early screening and diagnosis of preterm labor and pre-eclampsia, non-invasive prenatal screening, and…
